Neurotol Slow (Carbamazepine)

Carbamazepine, the active ingredient in Neurotol Slow, is an Anticonvulsant presented as an oral tablet for oral use. It is indicated for the management of epilepsy, trigeminal neuralgia and bipolar disorder, providing seizure control and pain relief in adult patients.

GNH USA supplies Neurotol Slow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet EU regulatory standards. The company handles export logistics, customs documentation and provides ongoing technical support to its global partners.

Carbamazepine is an anticonvulsant that modulates neuronal excitability in seizure‑related and neuropathic pain conditions.

- Epilepsy: reduces seizure frequency and severity in focal and generalized seizures. - Trigeminal neuralgia: alleviates paroxysmal facial pain episodes associated with the condition. - Bipolar disorder: stabilizes mood by decreasing manic episodes and preventing relapse.

Carbamazepine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Drowsiness: increased sleepiness or fatigue. - Nausea: mild stomach upset or queasiness. - Rash: mild skin irritation or redness. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Aplastic anemia: marked reduction in blood cell production. - Hepatotoxicity: liver enzyme elevation or liver injury. - Cardiac arrhythmia: irregular heart rhythm, especially in patients with conduction disorders.

When prescribing carbamazepine, clinicians should consider several precautionary measures to minimize risks.

- Monitor blood counts: regular CBC testing to detect agranulocytosis or aplastic anemia. - Assess liver function: periodic liver enzyme tests for hepatotoxicity. - Evaluate cardiac status: ECG monitoring in patients with pre‑existing conduction abnormalities. - Avoid abrupt discontinuation: taper dose gradually to prevent seizure recurrence. - Pregnancy risk: drug is Category D; discuss potential fetal risks with women of childbearing potential. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Carbamazepine interacts with several medicines, altering its own levels or those of co‑administered drugs.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): markedly reduce carbamazepine plasma concentrations. - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): increase carbamazepine levels and risk of toxicity. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring close INR monitoring. - Monoamine oxidase inhibitors: combined use can precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - Oral contraceptives: carbamazepine may reduce hormonal efficacy, leading to breakthrough bleeding. - Antidepressants (e.g., SSRIs): may increase risk of hyponatremia. - Antidiabetic agents (e.g., sulfonylureas): may require dose adjustments due to altered glucose control. - Antihistamines (e.g., diphenhydramine): may increase sedation.